Supplementary Figure 9: YAP1 knockdown sensitizes RAS-mutant melanoma and pancreatic cancer cells to MEK inhibition.
From: The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
(a,b) Effects of YAP1 knockdown using two independent shRNAs on trametinib sensitivity in (a) MM415 NRAS Q61L–mutant, (b) SK-MEL-2 NRAS Q61R–mutant melanoma cells. (c,d) Effects of YAP1 knockdown using two independent shRNAs on trametinib sensitivity in (c) HPAF-II KRAS G12D–mutant and (d) Panc 02.03 KRAS G12D–mutant pancreatic cancer cells. (e,f) Effects of YAP1 knockdown using two independent shRNAs on trametinib sensitivity in (e) MM415 NRAS Q61L–mutant and (f) SK-MEL-2 NRAS Q61R–mutant melanoma cells (shown is 7-d cell growth assessed by crystal violet staining assays, with quantification of the effects on viability under each condition).
